On this page
Bethanechol Chloride
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Bethanechol Chloride | 10 mg/1 | 857321 | — |
| Bethanechol Chloride | 25 mg/1 | 857321 | — |
| Bethanechol Chloride | 5 mg/1 | 857321 | — |
| Bethanechol Chloride | 50 mg/1 | 857321 | — |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Cholinergic Muscarinic Agonist [EPC] | EPC | 2 members — no class page |
| Cholinergic Muscarinic Agonists [MoA] | MoA | 8 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 040855-001 | BETHANECHOL CHLORIDE | TABLET | BETHANECHOL CHLORIDE | Prescription | AA | RS | |
| 040855-002 | BETHANECHOL CHLORIDE | TABLET | BETHANECHOL CHLORIDE | Prescription | AA | RS | |
| 040855-003 | BETHANECHOL CHLORIDE | TABLET | BETHANECHOL CHLORIDE | Prescription | AA | RS | |
| 040855-004 | BETHANECHOL CHLORIDE | TABLET | BETHANECHOL CHLORIDE | Prescription | AA | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | November 21, 2007 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260129). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Bethanechol Chloride Tablets, USP are indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Dosage must be individualized, depending on the type and severity of the condition to be treated. Preferably give the drug when the stomach is empty. If taken soon after eating, nausea and vomiting may occur. The usual adult oral dose ranges from 10 mg to 50 mg three or four times a day. The minimum effective dose is determined by giving 5 mg to 10 mg initially, and repeating the same amount at hourly intervals until satisfactory response occurs, or until a maximum of 50 mg has been given. The effects of the drug sometimes appear within 30 minutes, and are usually maximal within 60 to 90 minutes. The drug effects persist for about one hour. If necessary, the effects of the drug can be abolished promptly by atropine (see OVERDOSAGE ).
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Hypersensitivity to bethanechol chloride tablets, hyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or hypotension, vasomotor instability, coronary artery disease, epilepsy and parkinsonism. Bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question, or in the presence of mechanical obstruction; when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful, as following recent urinary bladder surgery, gastrointestinal resection and anastomosis, or when there is possible gastrointestinal obstruction; in bladder neck obstruction, spastic gastrointestinal disturbances, acute inflammatory lesions of the gastrointestinal tract, or peritonitis; or in marked vagotonia.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Adverse reactions are rare following oral administration of bethanechol chloride, but are more common following subcutaneous injection. Adverse reactions are more likely to occur when dosage is increased. The following adverse reactions have been observed: Body as a Whole: malaise Digestive: abdominal cramps or discomfort, colicky pain, nausea and belching, diarrhea, borborygmi, salivation Renal: urinary urgency Nervous System: headache Cardiovascular: a fall in blood pressure with reflex tachycardia, vasomotor response Skin: flushing producing a feeling of warmth, sensation of heat about the face, sweating Respiratory: bronchial constriction, asthmatic attacks Special Senses : lacrimation, miosis Causal Relationship Unknown: The following adverse reactions have been reported, and a causal relationship to therapy with bethanechol chloride has not been established: Body as a Whole: malaise Nervous System: seizures To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Drug Interactions
openFDA Drug LabelingDrug Interactions Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur. Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure.
Description
openFDA Drug LabelingDESCRIPTION Bethanechol chloride, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine. It is designated chemically as 2-[(aminocarbonyl) oxy]- N,N,N -trimethyl-1-propanaminium chloride. Its molecular formula is C 7 H 17 CIN 2 O 2 and its structural formula is: Bethanechol chloride, USP is a white, hygroscopic crystalline powder having a slight amine-like odor, freely soluble in water, and has a molecular weight of 196.68. Each tablet for oral administration contains 5 mg, 10 mg, 25 mg or 50 mg bethanechol chloride, USP. Bethanechol chloride Tablets, USP also contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose and sodium starch glycolate, Type A. The 25 mg and 50 mg tablets also contain D&C Yellow No.10 Aluminum Lake and FD&C Yellow No. 6 Aluminum Lake. Structural Formula
Overdosage
openFDA Drug LabelingOVERDOSAGE Early signs of overdosage are abdominal discomfort, salivation, flushing of the skin (“hot feeling”), sweating, nausea, and vomiting. Atropine Sulfate is a specific antidote. The recommended dose for adults is 0.6 mg. Repeat doses can be given every two hours, according to clinical response. The recommended dosage in infants and children up to 12 years of age is 0.01 mg/kg (to a maximum single dose of 0.4 mg) repeated every two hours as needed until the desired effect is obtained or adverse effects of atropine preclude further usage. Subcutaneous injection of atropine is preferred except in emergencies when the intravenous route may be employed. The oral LD 50 of bethanechol chloride is 1,510 mg/kg in the mouse.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Bethanechol Chloride Tablets, USP, 5 mg are supplied as white, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘571’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-571-10 Bottle of 500: NDC 65162-571-50 Bottle of 1000: NDC 65162-571-11 Bethanechol Chloride Tablets, USP, 10 mg are supplied as white, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘572’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-572-10 Bottle of 500: NDC 65162-572-50 Bottle of 1000: NDC 65162-572-11 Bethanechol Chloride Tablets, USP, 25 mg are supplied as yellow, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘573’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-573-10 Bottle of 500: NDC 65162-573-50 Bottle of 1000: NDC 65162-573-11 Bethanechol Chloride Tablets, USP, 50 mg are supplied as yellow, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘574’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-574-10 Bottle of 500: NDC 65162-574-50 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. This container is not intended for household use. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 05-2018-03
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: BETHANECHOL CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 60687-689-01 | 60687-689 | American Health Packaging | 100 BLISTER PACK in 1 CARTON (60687-689-01) / 1 TABLET in 1 BLISTER PACK (60687-689-11) | August 17, 2022 |
| 60687-700-01 | 60687-700 | American Health Packaging | 100 BLISTER PACK in 1 CARTON (60687-700-01) / 1 TABLET in 1 BLISTER PACK (60687-700-11) | December 15, 2022 |
| 65162-571-10 | 65162-571 | Amneal Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE (65162-571-10) | November 21, 2007 |
| 65162-571-11 | 65162-571 | Amneal Pharmaceuticals LLC | 1000 TABLET in 1 BOTTLE (65162-571-11) | November 21, 2007 |
| 65162-571-50 | 65162-571 | Amneal Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE (65162-571-50) | November 21, 2007 |
| 65162-572-10 | 65162-572 | Amneal Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE (65162-572-10) | November 21, 2007 |
| 65162-572-11 | 65162-572 | Amneal Pharmaceuticals LLC | 1000 TABLET in 1 BOTTLE (65162-572-11) | November 21, 2007 |
| 65162-572-50 | 65162-572 | Amneal Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE (65162-572-50) | November 21, 2007 |
| 65162-573-10 | 65162-573 | Amneal Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE (65162-573-10) | November 21, 2007 |
| 65162-573-11 | 65162-573 | Amneal Pharmaceuticals LLC | 1000 TABLET in 1 BOTTLE (65162-573-11) | November 21, 2007 |
| 65162-573-50 | 65162-573 | Amneal Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE (65162-573-50) | November 21, 2007 |
| 65162-574-10 | 65162-574 | Amneal Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE (65162-574-10) | November 21, 2007 |
| 65162-574-50 | 65162-574 | Amneal Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE (65162-574-50) | November 21, 2007 |
| 53746-571-01 | 53746-571 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-571-01) | April 15, 2022 |
| 53746-572-01 | 53746-572 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-572-01) | April 15, 2022 |
| 53746-573-01 | 53746-573 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-573-01) | April 15, 2022 |
| 53746-574-01 | 53746-574 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-574-01) | April 15, 2022 |
| 62135-755-90 | 62135-755 | Chartwell RX, LLC | 90 TABLET in 1 BOTTLE (62135-755-90) | January 17, 2024 |
| 62135-756-12 | 62135-756 | Chartwell RX, LLC | 120 TABLET in 1 BOTTLE (62135-756-12) | January 17, 2024 |
| 62135-757-12 | 62135-757 | Chartwell RX, LLC | 120 TABLET in 1 BOTTLE (62135-757-12) | January 17, 2024 |
| 62135-758-12 | 62135-758 | Chartwell RX, LLC | 120 TABLET in 1 BOTTLE (62135-758-12) | January 17, 2024 |
| 23155-934-01 | 23155-934 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | 100 TABLET in 1 BOTTLE (23155-934-01) | June 30, 2025 |
| 23155-935-01 | 23155-935 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | 100 TABLET in 1 BOTTLE (23155-935-01) | June 30, 2025 |
| 23155-936-01 | 23155-936 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | 100 TABLET in 1 BOTTLE (23155-936-01) | June 30, 2025 |
| 23155-937-01 | 23155-937 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | 100 TABLET in 1 BOTTLE (23155-937-01) | June 30, 2025 |
| 0832-0510-00 | 0832-0510 | Upsher-Smith Laboratories, LLC | 100 TABLET in 1 BOTTLE (0832-0510-00) | January 24, 2010 |
| 0832-0510-01 | 0832-0510 | Upsher-Smith Laboratories, LLC | 100 BLISTER PACK in 1 CARTON (0832-0510-01) / 1 TABLET in 1 BLISTER PACK (0832-0510-89) | January 24, 2010 |
| 0832-0510-10 | 0832-0510 | Upsher-Smith Laboratories, LLC | 1000 TABLET in 1 BOTTLE (0832-0510-10) | January 24, 2010 |
| 0832-0511-00 | 0832-0511 | Upsher-Smith Laboratories, LLC | 100 TABLET in 1 BOTTLE (0832-0511-00) | January 24, 2010 |
| 0832-0511-01 | 0832-0511 | Upsher-Smith Laboratories, LLC | 100 BLISTER PACK in 1 CARTON (0832-0511-01) / 1 TABLET in 1 BLISTER PACK (0832-0511-89) | January 24, 2010 |
| 0832-0511-10 | 0832-0511 | Upsher-Smith Laboratories, LLC | 1000 TABLET in 1 BOTTLE (0832-0511-10) | January 24, 2010 |
| 0832-0511-25 | 0832-0511 | Upsher-Smith Laboratories, LLC | 250 TABLET in 1 BOTTLE (0832-0511-25) | January 24, 2010 |
| 0832-0512-00 | 0832-0512 | Upsher-Smith Laboratories, LLC | 100 TABLET in 1 BOTTLE (0832-0512-00) | January 24, 2010 |
| 0832-0512-01 | 0832-0512 | Upsher-Smith Laboratories, LLC | 100 BLISTER PACK in 1 CARTON (0832-0512-01) / 1 TABLET in 1 BLISTER PACK (0832-0512-89) | January 24, 2010 |
| 0832-0512-10 | 0832-0512 | Upsher-Smith Laboratories, LLC | 1000 TABLET in 1 BOTTLE (0832-0512-10) | January 24, 2010 |
| 0832-0512-25 | 0832-0512 | Upsher-Smith Laboratories, LLC | 250 TABLET in 1 BOTTLE (0832-0512-25) | January 24, 2010 |
| 0832-0512-50 | 0832-0512 | Upsher-Smith Laboratories, LLC | 500 TABLET in 1 BOTTLE (0832-0512-50) | January 24, 2010 |
| 0832-0513-00 | 0832-0513 | Upsher-Smith Laboratories, LLC | 100 TABLET in 1 BOTTLE (0832-0513-00) | January 24, 2010 |
| 0832-0513-01 | 0832-0513 | Upsher-Smith Laboratories, LLC | 100 BLISTER PACK in 1 CARTON (0832-0513-01) / 1 TABLET in 1 BLISTER PACK (0832-0513-89) | January 24, 2010 |
| 0832-0513-10 | 0832-0513 | Upsher-Smith Laboratories, LLC | 1000 TABLET in 1 BOTTLE (0832-0513-10) | January 24, 2010 |
| 0832-0513-50 | 0832-0513 | Upsher-Smith Laboratories, LLC | 500 TABLET in 1 BOTTLE (0832-0513-50) | January 24, 2010 |
| 60687-689 | 60687-689 | American Health Packaging | — | August 17, 2022 |
| 60687-700 | 60687-700 | American Health Packaging | — | December 15, 2022 |
| 65162-571 | 65162-571 | Amneal Pharmaceuticals LLC | — | November 21, 2007 |
| 65162-572 | 65162-572 | Amneal Pharmaceuticals LLC | — | November 21, 2007 |
| 65162-573 | 65162-573 | Amneal Pharmaceuticals LLC | — | November 21, 2007 |
| 65162-574 | 65162-574 | Amneal Pharmaceuticals LLC | — | November 21, 2007 |
| 53746-571 | 53746-571 | Amneal Pharmaceuticals of New York LLC | — | April 15, 2022 |
| 53746-572 | 53746-572 | Amneal Pharmaceuticals of New York LLC | — | April 15, 2022 |
| 53746-573 | 53746-573 | Amneal Pharmaceuticals of New York LLC | — | April 15, 2022 |
| 53746-574 | 53746-574 | Amneal Pharmaceuticals of New York LLC | — | April 15, 2022 |
| 62135-755 | 62135-755 | Chartwell RX, LLC | — | October 26, 2007 |
| 62135-756 | 62135-756 | Chartwell RX, LLC | — | October 26, 2007 |
| 62135-757 | 62135-757 | Chartwell RX, LLC | — | October 26, 2007 |
| 62135-758 | 62135-758 | Chartwell RX, LLC | — | October 26, 2007 |
| 23155-934 | 23155-934 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | — | June 30, 2025 |
| 23155-935 | 23155-935 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | — | June 30, 2025 |
| 23155-936 | 23155-936 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | — | June 30, 2025 |
| 23155-937 | 23155-937 | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | — | June 30, 2025 |
| 0832-0510 | 0832-0510 | Upsher-Smith Laboratories, LLC | — | January 24, 2010 |
| 0832-0511 | 0832-0511 | Upsher-Smith Laboratories, LLC | — | January 24, 2010 |
| 0832-0512 | 0832-0512 | Upsher-Smith Laboratories, LLC | — | January 24, 2010 |
| 0832-0513 | 0832-0513 | Upsher-Smith Laboratories, LLC | — | January 24, 2010 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.